(Q34644127)

3 August 2017

title

Linezolid for treatment of chronic extensively drug-resistant tuberculosis (English)

1 reference

3 August 2017

0 references

1 reference

7

Laura E Via

1 reference

3 August 2017

Ray Y Chen

17

0 references

Clifton E Barry

object named as

Clifton E Barry

28

0 references

Veronique Dartois

25

object named as

Veronique Dartois

1 reference

3 August 2017

20

Dean Follmann

1 reference

3 August 2017

Myungsun Lee

1

1 reference

3 August 2017

Jongseok Lee

2

1 reference

3 August 2017

Matthew W Carroll

3

1 reference

3 August 2017

Hongjo Choi

4

1 reference

3 August 2017

Seonyeong Min

5

1 reference

3 August 2017

Taeksun Song

6

1 reference

3 August 2017

Lisa C Goldfeder

8

1 reference

3 August 2017

Eunhwa Kang

9

1 reference

3 August 2017

Boyoung Jin

10

1 reference

3 August 2017

Hyeeun Park

11

1 reference

3 August 2017

Hyunkyung Kwak

12

1 reference

3 August 2017

Hyunchul Kim

13

1 reference

3 August 2017

Han-Seung Jeon

14

1 reference

3 August 2017

Ina Jeong

15

1 reference

3 August 2017

Joon Sung Joh

16

1 reference

3 August 2017

Kenneth N Olivier

18

1 reference

3 August 2017

Pamela A Shaw

19

1 reference

3 August 2017

Sun Dae Song

21

1 reference

3 August 2017

Jong-Koo Lee

22

1 reference

3 August 2017

Dukhyoung Lee

23

1 reference

3 August 2017

Cheon Tae Kim

24

1 reference

3 August 2017

Seung-Kyu Park

26

1 reference

3 August 2017

Sang-Nae Cho

27

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 October 2012

1 reference

The New England Journal of Medicine

3 August 2017

published in

1 reference

3 August 2017

volume

367

1 reference

3 August 2017

issue

16

1 reference

3 August 2017

page(s)

1508-1518

1 reference

Rhabdomyolysis in a patient treated with linezolid for extensively drug-resistant tuberculosis

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Linezolid, the first oxazolidinone antibacterial agent

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Pharmacological issues of linezolid: an updated critical review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Linezolid in the treatment of multidrug-resistant tuberculosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Linezolid: a review of safety and tolerability

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

STREPTOMYCIN treatment of pulmonary tuberculosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

First linezolid-resistant clinical isolates of Mycobacterium tuberculosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Linezolid for the treatment of multidrug-resistant tuberculosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Clinical Pharmacokinetics of Linezolid, a Novel Oxazolidinone Antibacterial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Intrapulmonary pharmacokinetics of linezolid

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Oxazolidinones, a new class of synthetic antituberculosis agent in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Linezolid-associated toxic optic neuropathy: a report of 2 cases

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Ribosomal and non-ribosomal resistance to oxazolidinones: species-specific idiosyncrasy of ribosomal alterations

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3814175

Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India

26 October 2018

1 reference

12 December 2020

Repeated assessment of results in clinical trials of cancer treatment

1 reference

12 December 2020

The reliability and validity of the subjective peripheral neuropathy screen

1 reference

12 December 2020

In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1201964

1 reference

3 August 2017

1 reference

3 August 2017

1 reference